Checked 2026-11-10. Independent clinical review has not been completed. WADAFUK is independent of WADA and does not provide medical advice or an individual anti-doping determination.
Regulatory summary with limited context. A compound-specific science and safety review is still missing.
Prohibited at all times
2026 S4.1: prohibited at all times. Specified. [1]
S4.1 · 2026 rules apply from 1 January 2026. Any 2027 material below concerns future rules from 1 January 2027; it is not current clearance.
Evidence coverage
Only the anti-doping rule and name mapping were confirmed for this entry in this review. No clinical benefit, therapeutic approval or human safety claim is made. [1]
- Sparse coverage must not be mistaken for evidence of safety.
What remains uncertain
- Substance-specific pharmacology, clinical context, safety and consumer-exposure evidence were not sufficiently verified for publication.
- Chemical structure and stereochemical identity require separate reconciliation; no PubChem structure or identifier has been imported.
Check the sources.
These are concise editorial paraphrases of selected sources, not a systematic review or a reproduction of source tables. Access depth is shown for each reference; an abstract-only check cannot resolve details found only in a full paper.
- WADA 2026 Prohibited List ↗Accessed 2026-11-10 · Relevant official full-text sections opened
Printed pp. 3, 9–12: introduction, S3, S4 and S5 as applicable
Check the current official WADA List and the relevant anti-doping authority for your sport, product, route and circumstances. Do not stop or change necessary treatment based on this page. Ask a qualified clinician about health decisions. Missing evidence does not establish safety.